Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Heron Therapeutics (HRTX) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Heron Therapeutics (HRTX) over the last 12 years, with Q3 2025 value amounting to 10.71%.

  • Heron Therapeutics' EBIT Margin rose 28800.0% to 10.71% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.03%, marking a year-over-year increase of 198500.0%. This contributed to the annual value of 7.99% for FY2024, which is 790800.0% up from last year.
  • Heron Therapeutics' EBIT Margin amounted to 10.71% in Q3 2025, which was up 28800.0% from 4.4% recorded in Q2 2025.
  • Heron Therapeutics' 5-year EBIT Margin high stood at 10.23% for Q4 2024, and its period low was 269.43% during Q2 2021.
  • Moreover, its 5-year median value for EBIT Margin was 79.31% (2023), whereas its average is 109.52%.
  • In the last 5 years, Heron Therapeutics' EBIT Margin plummeted by -527200bps in 2021 and then surged by 1914100bps in 2022.
  • Quarter analysis of 5 years shows Heron Therapeutics' EBIT Margin stood at 259.2% in 2021, then surged by 74bps to 67.79% in 2022, then soared by 56bps to 29.85% in 2023, then surged by 134bps to 10.23% in 2024, then crashed by -205bps to 10.71% in 2025.
  • Its EBIT Margin stands at 10.71% for Q3 2025, versus 4.4% for Q2 2025 and 8.11% for Q1 2025.